Meticuly is a Top Prospect for Investment Opportunities, According to INSEAD
Meticuly has been named by INSEAD, one of the world’s leading and largest graduate business schools, as a top potential prospect for investment opportunities in Asia in its ‘Southeast Asia VC HealthTech Landscape’ report.
The report, based on a study conducted by INSEAD, takes an analytical review of the healthcare and e-Health space and trends, which areas are expected to grow the most, what are the key growth drivers and what are the key trends in upcoming years.
INSEAD looked at numerous startups and VCs currently active in the region to determine within each vertical the most promising startups for international finance corporations to explore.
The institution found that healthcare expenditure in Southeast Asia is on the rise, growing even faster than GDP. At the current pace, it is expected that by 2025, total healthcare spending could accelerate up to 740 billion USD from the current 425 billions USD. This growth is primarily driven by an ageing population (% of population above 60 will increase from 9.6% in 2016 to 21.1% in 2050, driven by the increased life expectancy of elders and reduced fertility rates of an increasingly wealthy population) and prevalence of non-communicable diseases.
“... Corporates and HealthTech ventures are increasingly entering into partnerships to scale digital health ... “
According to INSEAD, through its research and considering the international financial corporations’ development goals and objectives, from Thailand, Meticuly from was found to be a potentially investable start-up.
Dr. Boonrat Lohwongwatana, CEO and co-founder of Meticuly said, “we are delighted to be recognized in INSEAD’s study as a potential investment opportunity in Thailand’s healthcare industry. Through our partnerships with investors and healthcare institutions, we have been growing and making overwhelming progress in providing Thai patients and healthcare professionals with affordable and reliable bone implant solutions with our technology.”
INSEAD found that currently, Thailand’s universal healthcare system is highly centralized, expensive and will need changes in order to support its aging population, whether through decentralization of healthcare systems or tech innovations. There’s a looming shortage of healthcare professionals, and a rural-urban gap in terms of accessibility to high quality healthcare, providing an opportunity for technology to address some of these issues. The government is set on a goal to make Thailand the “number 1 Medical Hub of Asia” by pushing for support of its medical tourism industry, and providing incentives for research and development in technology and innovation.
Meticuly is a prime prospect in both healthcare and health technology as the company provides doctors and healthcare institutions with personalized bone implants that are designed individually based on each patient’s CT scans.
As the company simplifies it: The goal of any surgeon is to complete surgeries with the best clinical outcomes in the shortest amount of time. Meticuly works for doctors who operate on medical implants to achieve this goal with advanced AI-assisted software, high quality manufacturing, and an efficient workflow. For doctors, Meticuly redefines and improves the bone surgery process to enhance patients’ personalized care. For the patient, Meticuly produces a reliable yet affordable alternative solution.
INSEAD found that technology can play a key role in delivering convenient, cost-effective, and high-quality treatment. Technology and data can deliver the same convenience and cost savings found in other parts of the online economy, such as e-commerce. With telehealth, people in rural and other remote areas are now able to receive an online diagnosis and access digital resources to address their needs. This coincides with Meticuly’s workflow of providing custom 3D bone implants based on the patient’s CT scan. With its workflow, the company is able to shorten the entire process of providing doctors with bone implants for their patients – with reliability, accuracy and with more cost-effectively.